Table 1 Public procurement of antineoplastic agents used for treating breast cancer - purchase quantities in mg by purchaser category. Brazil, 2013–2019

Anastrozole 1 mg^a

10,838,515

41.25

8,803,262

33.50

2,913,665

11.09

3,722,340

14.17

26,277,782

Docetaxel 40 mg^b

12,097,460

45.50

8,352,420

31.41

1,834,800

6.90

4,304,760

16.19

26,589,440

Exemestane 25 mg^c

21,923,725

48.42

7,926,800

17.51

8,587,175

18.96

6,842,850

15.11

45,280,550

Letrozole 2.5 mg^a

2,109,253

58.52

196,850

5.46

1,040,350

28.86

257,963

7.16

3,604,415

Paclitaxel 6 mg^b

60,776,655

63.34

18,113,116

18.88

5,987,234

6.24

11,082,205

11.55

95,959,210

Tamoxifen 20 mg^a

394,563,360

54.89

205,193,800

28.55

26,791,300

3.73

92,260,920

12.84

718,809,382

Trastuzumab 440 mg^b

3,030,720

10.25

7,537,200

25.49

6,787,880

22.96

12,208,240

41.29

29,564,040

Vinorelbine 10 mg^d

2,058,470

57.79

854,040

23.98

233,700

6.56

415,870

11.67

3,562,080

Vinorelbine 20 mg^d

1,047,080

40.60

1,063,520

41.24

428,380

16.61

40,000

1.55

2,578,980

Vinorelbine 30 mg^d

3,007,350

56.41

1,512,930

28.38

750,600

14.08

60,000

1.13

5,330,880